G. Attard

932 total citations
28 papers, 271 citations indexed

About

G. Attard is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, G. Attard has authored 28 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 14 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Oncology. Recurrent topics in G. Attard's work include Prostate Cancer Treatment and Research (22 papers), Radiopharmaceutical Chemistry and Applications (13 papers) and Cancer, Lipids, and Metabolism (5 papers). G. Attard is often cited by papers focused on Prostate Cancer Treatment and Research (22 papers), Radiopharmaceutical Chemistry and Applications (13 papers) and Cancer, Lipids, and Metabolism (5 papers). G. Attard collaborates with scholars based in United Kingdom, United States and France. G. Attard's co-authors include Ehab Mostafa, Abdelaziz Abdellatif, Helmut Baltruschat, Johann S. de Bono, Shahneen Sandhu, Karim Fizazi, Glenn Heller, C. Logothetis, Martin Fleisher and Howard I. Scher and has published in prestigious journals such as Advanced Materials, Journal of Clinical Oncology and Electrochimica Acta.

In The Last Decade

G. Attard

27 papers receiving 269 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Attard United Kingdom 7 165 94 56 53 48 28 271
Shengjie Yin China 11 22 0.1× 90 1.0× 56 1.0× 45 0.8× 51 1.1× 22 373
Haixia Jia China 11 75 0.5× 140 1.5× 150 2.7× 47 0.9× 32 0.7× 31 413
Zeyang Wang China 10 50 0.3× 66 0.7× 68 1.2× 38 0.7× 15 0.3× 45 378
Jinlin Hu China 10 85 0.5× 24 0.3× 71 1.3× 29 0.5× 14 0.3× 16 242
Yuxiang Deng China 12 74 0.4× 65 0.7× 174 3.1× 54 1.0× 18 0.4× 34 360
Daniel Breadner Canada 11 180 1.1× 105 1.1× 165 2.9× 3 0.1× 42 0.9× 49 472
Gaofeng Shi China 13 171 1.0× 50 0.5× 109 1.9× 36 0.7× 251 5.2× 52 425
A. Wang United States 5 83 0.5× 87 0.9× 261 4.7× 14 0.3× 18 0.4× 10 401
X. Yang China 9 50 0.3× 20 0.2× 54 1.0× 36 0.7× 10 0.2× 12 270

Countries citing papers authored by G. Attard

Since Specialization
Citations

This map shows the geographic impact of G. Attard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Attard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Attard more than expected).

Fields of papers citing papers by G. Attard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Attard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Attard. The network helps show where G. Attard may publish in the future.

Co-authorship network of co-authors of G. Attard

This figure shows the co-authorship network connecting the top 25 collaborators of G. Attard. A scholar is included among the top collaborators of G. Attard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Attard. G. Attard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
N., Kim, Elena Castro, G. Attard, et al.. (2025). Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial. European Urology Oncology. 8(4). 986–998. 1 indexed citations
2.
3.
4.
Ravi, Praful, Wanling Xie, Marc Buyse, et al.. (2024). Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. European Urology. 87(2). 217–224. 2 indexed citations
5.
6.
Smith, Clayton, J. Proudfoot, Paul C. Boutros, et al.. (2023). Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. European Urology Oncology. 6(2). 224–227. 2 indexed citations
7.
8.
Jayaram, Anuradha, Anna Wingate, Daniel Wetterskog, et al.. (2021). Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Annals of Oncology. 32(6). 726–735. 36 indexed citations
9.
Santaolalla, Aida, Tim Hulsen, Hashim U. Ahmed, et al.. (2021). The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer. Frontiers in Artificial Intelligence. 4. 769582–769582. 5 indexed citations
10.
11.
12.
Bianchini, Diletta, Yohann Loriot, E. Ileana, et al.. (2012). Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and MDV3100: A Multicentre Study. Annals of Oncology. 23. ix304–ix305. 2 indexed citations
13.
14.
Olmos, David, J. W. Clark, Daniel Brewer, et al.. (2011). An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome.. Journal of Clinical Oncology. 29(15_suppl). 4577–4577. 1 indexed citations
15.
Abdellatif, Abdelaziz, et al.. (2010). Electrooxidation of ethanol at polycrystalline and platinum stepped single crystals: A study by differential electrochemical mass spectrometry. Electrochimica Acta. 55(27). 7951–7960. 61 indexed citations
16.
Folkerd, Elizabeth, G. Attard, David P. Dearnaley, et al.. (2009). Abiraterone acetate: the novel application of a CYP450c17 inhibitor to the treatment of both prostate and breast cancer. 19. 1 indexed citations
17.
Bono, Johann S. de, G. Attard, Catherine Parker, et al.. (2008). Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). Journal of Clinical Oncology. 26(15_suppl). 5005–5005. 15 indexed citations
18.
Grech, Victor, et al.. (2007). Kawasaki disease presenting as hepatitis. Annals of Tropical Paediatrics. 27(4). 303–306. 6 indexed citations
19.
Li, Zhong, Jana Andžāne, Joseph M. Tobin, et al.. (2007). A Supercritical‐Fluid Method for Growing Carbon Nanotubes. Advanced Materials. 19(19). 3043–3046. 11 indexed citations
20.
Attard, G., et al.. (1996). Language-like features in DNA: transposable element footprints in the genome. Europhysics Letters (EPL). 36(5). 391–396. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shengjie Yin Breakdown of academic impact, for papers by Haixia Jia Breakdown of academic impact, for papers by Zeyang Wang Breakdown of academic impact, for papers by Jinlin Hu Breakdown of academic impact, for papers by Yuxiang Deng Breakdown of academic impact, for papers by Daniel Breadner Breakdown of academic impact, for papers by Gaofeng Shi Breakdown of academic impact, for papers by A. Wang Breakdown of academic impact, for papers by X. Yang
Rankless by CCL
2026